A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants were randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).
Inclusion Criteria:
Exclusion Criteria:
Cancer-Specific Exclusions:
General Medical Exclusions:
Exclusion Criteria Related to Medications:
Sacramento, California 95825, United States
Norwich, Connecticut 06360, United States
Deerfield Beach, Florida Suite 200, United States
St. Petersburg, Florida 33705, United States
Carrollton, Georgia 30117, United States
Berlin, 13353, Germany
Koblenz Am Rhein, 56073, Germany
Villingen-Schwenningen, 78052, Germany
Beer Yaakov, 70300, Israel
Petach Tiqwa, 49100, Israel
Rambam, 3525408, Israel
Avellino, Campania 83100, Italy
Naples, Campania 80131, Italy
Naples, Campania 80131, Italy
Perugia, Umbria 06129, Italy
Castellon de LA Plana/castello de LA Plana, Castellon 12002, Spain
S. Cristobal de La Laguna, Tenerife 38320, Spain